IRWD (Ironwood Pharmaceuticals) Cyclically Adjusted Revenue per Share: $2.77 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRWD Ironwood Pharmaceuticals Inc IRWD
65 GF Score
Price $4.12
GF Value $4.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ironwood Pharmaceuticals Cyclically Adjusted Revenue per Share?

Ironwood Pharmaceuticals IRWD -5.72% 65 Cyclically Adjusted Revenue per Share is $2.77 as of Jun. 2026. GuruFocus rates IRWD with a GF Score™ of 65/100 and a GF Value™ of $4.55 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ironwood Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was $0.676. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.77 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Ironwood Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 4.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ironwood Pharmaceuticals was 14.00% per year. The lowest was 6.80% per year. And the median was 10.90% per year.

As of today (2026-08-20), Ironwood Pharmaceuticals's current stock price is $4.12. Ironwood Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $2.77. Ironwood Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ironwood Pharmaceuticals was 11.90. The lowest was 0.22. And the median was 5.74.


Ironwood Pharmaceuticals  (NAS:IRWD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ironwood Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.12/2.77
=1.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ironwood Pharmaceuticals was 11.90. The lowest was 0.22. And the median was 5.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ironwood Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Ironwood Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ironwood Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ironwood Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 2.06 2.37 2.58 2.68

Ironwood Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.66 2.71 2.68 2.73 2.77

IRWD vs TLRY, AQST, ELTP: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


IRWD
65GF Score
Ironwood Pharmaceuticals Inc IRWD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ironwood Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ironwood Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.676/333.9520*333.9520
=0.676

Current CPI (Jun. 2026) = 333.9520.

Ironwood Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.455 241.428 0.629
201612 0.598 241.432 0.827
201703 0.353 243.801 0.484
201706 0.437 244.955 0.596
201709 0.581 246.819 0.786
201712 0.629 246.524 0.852
201803 0.458 249.554 0.613
201806 0.533 251.989 0.706
201809 0.429 252.439 0.568
201812 0.848 251.233 1.127
201903 0.444 254.202 0.583
201906 0.656 256.143 0.855
201909 0.836 256.759 1.087
201912 0.805 256.974 1.046
202003 0.500 258.115 0.647
202006 0.559 257.797 0.724
202009 0.646 260.280 0.829
202012 0.721 260.474 0.924
202103 0.547 264.877 0.690
202106 0.636 271.696 0.782
202109 0.628 274.310 0.765
202112 0.706 278.802 0.846
202203 0.515 287.504 0.598
202206 0.526 296.311 0.593
202209 0.589 296.808 0.663
202212 0.577 296.797 0.649
202303 0.557 301.836 0.616
202306 0.691 305.109 0.756
202309 0.609 307.789 0.661
202312 0.753 306.746 0.820
202403 0.475 312.332 0.508
202406 0.594 314.175 0.631
202409 0.572 315.301 0.606
202412 0.552 315.605 0.584
202503 0.256 319.799 0.267
202506 0.482 322.561 0.499
202509 0.687 324.800 0.706
202512 0.294 324.054 0.303
202603 0.639 330.213 0.646
202606 0.676 333.952 0.676

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.77 mean?
Ironwood Pharmaceuticals (IRWD) has a Cyclically Adjusted Revenue per Share of $2.77 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ironwood Pharmaceuticals and its competitors.
Is Ironwood Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Ironwood Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $2.77. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to TLRY and AQST?
Ironwood Pharmaceuticals' Cyclically Adjusted Revenue per Share of $2.77 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ironwood Pharmaceuticals and its competitors. Ironwood Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (IRWD) is currently considered Fairly Valued. The stock's GF Value™ is $4.55, compared to a current price of $4.12 — trading 9.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.77. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ironwood Pharmaceuticals (IRWD), the current Cyclically Adjusted Revenue per Share is $2.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?

Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued. The current stock price of $4.12 is trading 9.5% below its estimated GF Value™ of $4.55. GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.

Key valuation signals for IRWD:

  • Cyclically Adjusted Revenue per Share: $2.77
  • GF Value™: $4.55 vs. price of $4.12 (9.5% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ironwood Pharmaceuticals Business Description

Other Exchanges I76:Germany
Address 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score

Get the complete analysis for IRWD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price
$4.55
GF Value